We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Xeris ...

most likely drawn from the glucagon-like peptide 1 class of drugs. As I wrote in my last note on Structure: The most famous examples of GLP-1 agonist drugs are Novo Nordisk's (NVO) semaglutide ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

Structure Therapeutics (NASDAQ ... an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...

Type 2 diabetes mellitus (T2DM) is a prevalent yet complex metabolic disorder that has shown a rising incidence over the past few decades. Recent research has identified flavonoids as compounds ...

With clinical trials results trickling in, “antiaging” drugs that clear away senescent cells are proving to be promising — ...

Flavonoids are categorized into several subclasses based on their chemical structure, including flavonols ... through various peptides, including glucagon-like peptide-1 (GLP-1), glucose-dependent ...